轻度认知障碍或痴呆患者中淀粉样蛋白PET阳性的种族与民族差异:痴呆-淀粉样蛋白成像证据(IDEAS)队列研究的二次分析
该研究为IDEAS单臂多中心队列的二次分析,纳入17107例符合淀粉样蛋白PET适用标准的轻度认知障碍或痴呆患者,比较不同种族和民族间淀粉样蛋白PET阳性比例及调整后比值比。结果显示,亚洲、黑人和西班牙裔参与者淀粉样蛋白PET阳性的比值均低于白人参与者,提示认知障碍潜在病因可能存在差异。
要点
- 在1:1匹配分析中,白人参与者淀粉样蛋白PET阳性比例高于亚洲参与者(57.8% vs 45.4%,P=0.001)和西班牙裔参与者(61.8% vs 54.5%,P=0.003),与黑人参与者无显著差异(P=0.13)。
- 调整后模型显示,亚洲(OR 0.47)、黑人(OR 0.71)和西班牙裔(OR 0.68)参与者淀粉样蛋白PET阳性的比值均低于白人参与者(P均<0.001)。
- 作者认为,这些种族和民族差异可能反映认知障碍潜在病因的不同,并可能指导未来的治疗和预防策略。
核心结论
- 本研究发现轻度认知障碍和痴呆患者中淀粉样蛋白PET阳性存在种族和民族差异,可能提示认知障碍潜在病因不同,并可能指导未来治疗和预防方法。
研究设计与样本
- IDEAS研究的二次分析,IDEAS为单臂多中心队列研究,纳入2016年2月至2017年9月符合淀粉样蛋白PET成像适用标准的医疗保险受益人,随访至2018年1月,数据于2020年4月至2022年1月分析。
- IDEAS研究在美国595家痴呆专科诊所入组21949例参与者,本分析排除4842例(22%),最终纳入17107例轻度认知障碍或痴呆并接受淀粉样蛋白PET的个体。
主要发现
- 纳入分析的17107例参与者中,亚洲321例、黑人635例、西班牙裔829例、白人15322例;中位年龄75岁(范围65-105岁),女性8769例(51.3%),男性8338例(48.7%)。
- 在最佳1:1匹配分析(n=3154)中,白人参与者淀粉样蛋白PET阳性比例为57.8%(181/313;95%CI 52.3-63.2),亚洲参与者为45.4%(142/313;95%CI 39.9-50.9),组间比较P=0.001。
- 在最佳1:1匹配分析中,白人参与者淀粉样蛋白PET阳性比例为61.8%(482/780;95%CI 58.3-65.1),西班牙裔参与者为54.5%(425/780;95%CI 51.0-58.0),组间比较P=0.003。
- 在最佳1:1匹配分析中,白人参与者淀粉样蛋白PET阳性比例为58.4%(359/615;95%CI 54.4-62.2),黑人参与者为54.1%(333/615;95%CI 50.2-58.0),组间比较P=0.13。
- 在调整模型中,与白人参与者相比,亚洲参与者淀粉样蛋白PET阳性的比值比为0.47(95%CI 0.37-0.59;P<0.001),黑人参与者为0.71(95%CI 0.60-0.84;P<0.001),西班牙裔参与者为0.68(95%CI 0.59-0.79;P<0.001)。
关键数值与推荐
- 淀粉样蛋白PET阳性比例:白人 vs 亚洲为57.8% vs 45.4%(P=0.001),白人 vs 西班牙裔为61.8% vs 54.5%(P=0.003),白人 vs 黑人为58.4% vs 54.1%(P=0.13)。
- 调整后淀粉样蛋白PET阳性比值比:亚洲 vs 白人为0.47(95%CI 0.37-0.59;P<0.001),黑人 vs 白人为0.71(95%CI 0.60-0.84;P<0.001),西班牙裔 vs 白人为0.68(95%CI 0.59-0.79;P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Racial and ethnic groups with higher rates of clinical Alzheimer disease (AD) are underrepresented in studies of AD biomarkers, including amyloid positron emission tomography (PET). OBJECTIVE: To compare amyloid PET positivity among a diverse cohort of individuals with mild cognitive impairment (MCI) or dementia. DESIGN, SETTING, AND PARTICIPANTS: Secondary analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS), a single-arm multisite cohort study of Medicare beneficiaries who met appropriate-use criteria for amyloid PET imaging between February 2016 and September 2017 with follow-up through January 2018. Data were analyzed between April 2020 and January 2022. This study used 2 approaches: the McNemar test to compare amyloid PET positivity proportions between matched racial and ethnic groups and multivariable logistic regression to assess the odds of having a positive amyloid PET scan. IDEAS enrolled participants at 595 US dementia specialist practices. A total of 21 949 were enrolled and 4842 (22%) were excluded from the present analysis due to protocol violations, not receiving an amyloid PET scan, not having a positive or negative scan, or because of small numbers in some subgroups. EXPOSURES: In the IDEAS study, participants underwent a single amyloid PET scan. MAIN OUTCOMES AND MEASURES: The main outcomes were amyloid PET positivity proportions and odds. RESULTS: Data from 17 107 individuals (321 Asian, 635 Black, 829 Hispanic, and 15 322 White) with MCI or dementia and amyloid PET were analyzed between April 2020 and January 2022. The median (range) age of participants was 75 (65-105) years; 8769 participants (51.3%) were female and 8338 (48.7%) were male. In the optimal 1:1 matching analysis (n = 3154), White participants had a greater proportion of positive amyloid PET scans compared with Asian participants (181 of 313; 57.8%; 95% CI, 52.3-63.2 vs 142 of 313; 45.4%; 95% CI, 39.9-50.9, respectively; P = .001) and Hispanic participants (482 of 780; 61.8%; 95% CI, 58.3-65.1 vs 425 of 780; 54.5%; 95% CI, 51.0-58.0, respectively; P = .003) but not Black participants (359 of 615; 58.4%; 95% CI, 54.4-62.2 vs 333 of 615; 54.1%; 95% CI, 50.2-58.0, respectively; P = .13). In the adjusted model, the odds of having a positive amyloid PET scan were lower for Asian participants (odds ratio [OR], 0.47; 95% CI, 0.37-0.59; P < .001), Black participants (OR, 0.71; 95% CI, 0.60-0.84; P < .001), and Hispanic participants (OR, 0.68; 95% CI, 0.59-0.79; P < .001) compared with White participants. CONCLUSIONS AND RELEVANCE: Racial and ethnic differences found in amyloid PET positivity among individuals with MCI and dementia in this study may indicate differences in underlying etiology of cognitive impairment and guide future treatment and prevention approaches.
引用
- Wilkins CH, Windon CC, Dilworth-Anderson P, et al. Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia: A Secondary Analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Cohort Study. JAMA Neurol. 2022. PMID: 36190710. doi:10.1001/jamaneurol.2022.3157
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。